About
Team
Senior management team
Investment Team
Portfolio
Recent Case
News
Company News
Industry News
Media Coverage
Contact
Contact information
News
News Details
Your location:
Home
→
News
→
Company News
科创板新药第一股鸣钟上交所
Date:
2019-08-12
Views:
11
今早,上海证券交易所
科创板新药第一股微芯生物
上市仪式举行。中国多层次资本市场从此开启了新的篇章。
微芯生物(股票代码为“688321”)股价首日高开511%。
公司成立于2001年,专注于原创新分子实体药物,覆盖肿瘤、代谢疾病、免疫性疾病三大治疗领域,属于上海证券交易所科创板企业中要求的坚持面向世界科技前沿、符合国家战略、拥有关键核心技术、科技创新能力突出,具有较强成长性的生物医药产业的科技创新企业。
微芯生物目前具有14个在研项目储备,其中8个候选药物均为机制新颖的新分子实体。
西达本胺片是中国
首个以II期临床试验结果获批上市的国家1类原创新药
,亦是目前中国唯一治疗外周T细胞淋巴瘤的药物。
国家1类新药具有非常高的创新性,基本上
代表了我国药品注册分类中药物创新的最高水平
。
倚锋资本创始人朱晋桥与微芯生物董事长鲁先平博士
倚锋资本创始人朱晋桥与蒋华良院士以及投资人合影
微芯生物是国家“创新药物孵化基地”、“国家高新技术企业”,独立承担了多项国家“863“计划、“十五”、“十一五”、“十二五”及“十三五”国家重大科技专项及“重大新药创制”项目。
通过技术研发降低了社会医疗成本,突破发达国家在药物领域对中国的技术封锁。本次资金将
用于支持未来高质量产品的开发,实现资源的优化配置,通过研发驱动增长的模式提升研发能力
,投向科技创新领域。
Previous:
China's first new crown oral drug has be
Next:No
Related News
/
Recommended news
More
National Health Commission: azvidin tablets were included in the diagnosis and treatment plan of nov
2022
-
08
-
10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
More
The successful submission of the first share of the new crown oral drug is welcomed by The Hong Kong
2022
-
08
-
05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
More
Apexigen successfully listed on Nasdaq!
2022
-
08
-
01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
More
China's first new crown oral drug has been approved for marketing!
2022
-
07
-
25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
More
Home
Team
Portfolio
News
Contact
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
粵ICP備09063742號-1
粤公网安备44030402002338号
Sitemap
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务